Ogami Takuya, Chetkof Ethan, Bonatti Johannes O, Pantelis Christopher, Waterford Stephen D, Ferdinand Francis D, Hasan Irsa S, Serna-Gallegos Derek, Kaczorowski David J, Chu Danny, Thoma Floyd W, Sultan Ibrahim
Division of Cardiac Surgery, Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, Pa.
Department of Cardiothoracic Surgery, Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pa.
JTCVS Open. 2025 Jun 23;26:94-103. doi: 10.1016/j.xjon.2025.06.009. eCollection 2025 Aug.
Previous randomized controlled trials demonstrated comparable outcomes between posterior leaflet resections and neochord implantation in mitral valve (MV) repair. However, these studies were limited up to 1-year follow-up, and more recent evidence suggested that leaflet resections may offer superior long-term outcomes.
All patients who underwent MV repair with either resection or neochord implantation for posterior leaflet pathology between October 2011 and July 2024 were included. Propensity-score matching was used.
A total of 457 patients underwent posterior leaflet reconstruction, with 334 (73.1%) requiring leaflet resection (resection group) and 123 (26.9%) receiving neochordae (neochord group). The median [interquartile range] follow-up for survival and reintervention was 5.93 [2.00, 9.09] and 5.48 [1.84, 9.02] years, respectively. Overall, the mean age was 63.9 years, and the mean ejection fraction was 58.9%. Robotic-assisted surgery was performed in 28.9% (n = 132). The 30-day mortality was 2.4% (n = 11). Propensity-score matching provided 119 patients in each group. Kaplan-Meier curves demonstrated similar survival at 5 years between these groups (93.1 ± 2.8% in the resection group and 89.6 ± 3.1% in the neochord group, = .5). However, the neochord group had a greater cumulative incidence of reoperative MV surgery (8.0% vs 0.9% at 5 years in the resection group, = .01).
Neochordae were implanted in 27.3% of patients undergoing MV repair. Neochord implantation was associated with a greater risk of MV reintervention in the long term. Careful patient selection and technical considerations are important when choosing the repair method.
既往随机对照试验表明,二尖瓣(MV)修复术中后叶切除术与新腱索植入术的预后相当。然而,这些研究的随访时间限制在1年以内,而最近的证据表明,叶切除术可能带来更好的长期预后。
纳入2011年10月至2024年7月期间因后叶病变接受MV修复术(切除术或新腱索植入术)的所有患者。采用倾向评分匹配法。
共有457例患者接受了后叶重建,其中334例(73.1%)需要进行叶切除术(切除组),123例(26.9%)接受了新腱索植入(新腱索组)。生存和再次干预的中位[四分位间距]随访时间分别为5.93[2.00,9.09]年和5.48[1.84,9.02]年。总体而言,平均年龄为63.9岁,平均射血分数为58.9%。28.9%(n = 132)的患者接受了机器人辅助手术。30天死亡率为2.4%(n = 11)。倾向评分匹配后每组有119例患者。Kaplan-Meier曲线显示,两组在5年时的生存率相似(切除组为93.1±2.8%,新腱索组为89.6±3.1%,P = 0.5)。然而,新腱索组再次进行MV手术的累积发生率更高(5年时切除组为0.9%,新腱索组为8.0%,P = 0.01)。
在接受MV修复术的患者中,27.3%植入了新腱索。长期来看,新腱索植入与MV再次干预的风险更高相关。选择修复方法时,仔细的患者选择和技术考量很重要。